The Ras/Raf/MEK/ERK (extracellular signal-regulated kinase) pathway is primarily responsible for mitogenesis in metazoans, and mutational activation of this pathway is common in cancer. A variety of selective chemical inhibitors directed against the mitogen-activated protein kinase pathway are now available for clinical investigation and thus the determination of the importance of each of the kinases in oncogenesis is paramount. We investigated the role of two Raf kinases, B-Raf and C-Raf, in Ras oncogenesis, and found that although B-Raf and C-Raf have overlapping functions in primary mesenchymal cells, C-Raf but not B-Raf is required for the proliferative effects of K-Ras G12D in primary epithelial cells. Furthermore, in a lung cancer mouse model, C-Raf is essential for tumor initiation by oncogenic K-Ras G12D , whereas B-Raf is dispensable for this process. Our findings reveal that K-Ras G12D elicits its oncogenic effects primarily through C-Raf and suggest that selective C-Raf inhibition could be explored as a therapeutic strategy for K-Ras-dependent cancers.
INTRODUCTION
Activating mutations in Ras genes are observed in approximately 30% of human cancers ( 1 ) . Ras stimulates multiple downstream effector pathways, which are constitutively activated in a growth factor-independent fashion in cancer cells expressing oncogenic Ras ( 2 ) . Despite extensive efforts, targeted therapies against Ras were largely unsuccessful in clinical trials ( 3 ) , and thus pharmacological inhibition of Ras effector pathways may represent a more feasible approach to eradicate Ras-mutant cancers.
The contribution of Ras effector pathways to Rasmediated transformation has been studied in detail in human and murine cells (4) (5) (6) . These studies found that the OF2 | CANCER DISCOVERY JULY 2011 www.aacrjournals.org Karreth et al. 
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In this study, we genetically ablated B-Raf or C-Raf expression in K-Ras G12D -mutant primary cells in vitro as well as in lung epithelial cells in vivo to evaluate the contribution of individual Raf proteins to K-Ras G12D -mediated transformation. Our genetic analysis reveals that C-Raf is uniquely required for K-Ras G12D -driven transformation of epithelial cells in vitro and in vivo.
RESULTS

effect of raf Loss on K-ras
G12D -Mediated Transformation of Mouse embryonic fibroblasts
Endogenous expression of oncogenic K-Ras G12D partially transforms mouse embryonic fibroblasts (MEF) as indicated by immortality, elevated proliferation rates, and the ability to form foci under confluent culture condition (14) . importance of MAPK pathway deregulation for transformation by Ras is emphasized by the prevalence of B-Raf mutations. These mutants exquisitely activate the MAPK pathway and have been observed in cancer types that frequently carry Ras mutations, for example, in melanoma (N-Ras) as well as in lung, colon, and ovary (K-Ras) (9) . Furthermore, the occurrence of activated extracellular signal-regulated kinase (ERK)1/2 in lung cancer specimens is associated with a poor prognosis (10) . Importantly, several distinct mitogenactivated protein/ERK (MEK) inhibitors showed efficacy in the context of Ras-driven carcinoma cells in culture and xenografts, and are currently being assessed in clinical trials. In addition, pharmacological inhibition of both MEK and PI3K/target of rapamycin (11) in a K-Ras-mutant mouse model of early lung cancer (12) resulted in tumor regression, indicating that concurrent targeting of these pathways may have clinical benefits. Potent B-Raf-specific and pan-Raf inhibitors are being tested in clinical trials for cancers that carry B-Raf mutations (13). Such Raf inhibitors could also be clinically beneficial in malignancies harboring activating genetic lesions in K-Ras, provided that the Raf/ MEK/ERK pathway critically contributes to tumorigenesis induced by oncogenic K-Ras. To evaluate the suitability of Raf inhibitors for the treatment of K-Ras-mutant cancers, the role of Raf proteins in K-Ras oncogenesis needs to be established. Error bars represent ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001. G12D , and C-Raf Δ/Δ ; K-Ras G12D cells or with Ad-Mock. Ablation of B-Raf expression in otherwise wild-type BMK cells had no effect on proliferation (Fig. 2B ) or pERK and cyclin D1 expression ( Supplementary Fig. 3A ). Similar to K-Ras G12D -mutant BMK cells, activation of K-Ras G12D in the absence of B-Raf elevated proliferation of B-Raf Δ/Δ ; K-Ras G12D BMK cells (Fig. 2B) . These data indicate that B-Raf is dispensable for proliferation of wild-type and K-Ras-mutant epithelial cells in vitro.
In contrast, C-Raf Δ/Δ BMK cells proliferated less than wild-type control cells (Fig. 2C) , and accumulated in the G 2 to M-phase of the cell cycle ( Supplementary Fig. 3A) . No changes in pERK and only modest and heterogeneous changes in cyclin D1 levels were observed ( Supplementary  Fig. 3B ). Reduced cell numbers could not be attributed to apoptosis in the absence of C-Raf because the levels of cleaved caspase 3 and cleaved PARP did not increase upon C-Raf deletion ( Supplementary Fig. 3C ), implying that C-Raf may have additional functions in BMK cells. Interestingly, C-Raf Δ/Δ ; K-Ras G12D BMK cells did not display an increase in proliferation compared to control cells infected with Ad-Mock (Fig. 2C) , suggesting that oncogenic K-Ras G12D could not override the proliferative defect of BMK cells elicited by the absence of C-Raf. Cell-cycle analysis of BMK cells revealed that expression of oncogenic K-Ras G12D resulted in a larger proportion of cells in G 1 and S-phase and fewer cells in G 2 to M phase (Fig. 2D ), similar to endogenous expression of K-Ras G12D in MEFs (14) . The absence of B-Raf had no impact on the cell-cycle profile of K-Ras G12D -mutant BMK cells, whereas the C-Raf Δ/Δ ; K-Ras G12D BMK cells displayed cell-cycle distribution similar to wild-type control cells (Fig. 2D) , thus corroborating the proliferation analysis ( Fig. 2A-C) .
Expression of K-Ras G12D in MEFs induced the expression of several cell-cycle regulatory proteins (14) . We determined the expression levels of cell-cycle proteins in BMK cells to address if the absence of C-Raf alters the induction of such proteins, thereby rescuing the proliferation defect of K-Ras G12D -expressing cells. K-Ras G12D modestly increased phosphorylation of ERK and expression of CDK4, which was negated by depletion of either B-Raf or C-Raf ( Fig. 2E and F, and data not shown). Moreover, induction of cyclin D1 expression in response to K-Ras G12D was diminished in the absence of C-Raf but not B-Raf ( Fig. 2D and E) . Other cell-cycle regulators were not induced by K-Ras G12D or affected by Raf deficiency (data not shown). In addition, RNAi-mediated depletion of cyclin D1 in K and BBK BMK cells resulted in a markedly reduced number of cells in S-phase, as measured by bromodeoxyuridine incorporation (Supplementary Fig. 3D ). Thus, impaired upregulation of cyclin D1 in the absence of C-Raf may diminish the proliferative response of BMK cells to expression of K-Ras Supplementary Fig. 1C Fig. 1C ). Interestingly, under low and normal serum conditions deletion of B-Raf or C-Raf slightly decreased or elevated, respectively, steady-state phosphorylated ERK (pERK) levels (Fig. 1B) . However, only the increase in pERK in C-Raf-depleted cells grown in 2% serum was statistically significant. Hence, modest differences in steady-state pERK levels did not correlate with induction of proliferation in response to oncogenic K-Ras. To unequivocally investigate whether Raf deficiency alters MAPK activation, ERK phosphorylation in response to serum stimulation was examined. Notably, the kinetics of MAPK activation of serum-starved and re-stimulated K-Ras G12D , B-Raf Δ/Δ ; K-Ras G12D , and C-Raf Δ/Δ ; K-Ras G12D MEFs were comparable ( Supplementary Fig. 1D ). These findings indicate that loss of either B-Raf or C-Raf alone does not abrogate oncogenic transformation by K-Ras G12D and that B-Raf and C-Raf may have overlapping functions in MEFs.
Because genetic ablation of either B-Raf or C-Raf alone had no impact, the effect of combined depletion of B-Raf and C-Raf on K-Ras ; K-Ras LSL control cells (Fig. 1C) . Moreover, this rescue of the proliferation defect in K-Ras G12D -mutant MEFs was accompanied by a modest decrease in pERK and a more substantial decrease in cyclin D1, a known target of the MAPK pathway (Fig. 1D ). Knockdown of C-Raf in BBK MEFs similarly rescued proliferation (data not shown). These data suggest that K-Ras G12D signals through both B-Raf and C-Raf in MEFs, and combined deletion of both paralogues is necessary to suppress K-Ras-driven hyperproliferation of MEFs and activation of downstream targets.
Depletion of raf Proteins in K-ras
G12D -Mutant epithelial cells In Vitro
MEFs are a commonly used experimental system to assess the oncogenicity of mutant K-Ras; however, the number of conclusions that can be drawn from experiments using MEFs is limited concerning human cancer because K-Ras is typically mutated in epithelial cells. We therefore investigated whether B-Raf or C-Raf are critical for K-Ras Fig. 3B ), although the size of neoplasms was not affected by the absence of C-Raf (Fig. 3C ), suggesting that the lower number of neoplasms results in reduced lung tumor burden. Thus, K-Ras G12D -induced formation of alveolar and bronchiolar tumors is impaired in the absence of C-Raf (Fig. 3D) . Interestingly, although B-Raf fl/fl ; K-Ras LSL mice displayed a specific reduction in the number of BHs but not AAHs or adenomas (Fig. 3B) , the size of all neoplasms was reduced ( LSL mice on the same genetic background were infected with Ad-Cre via intranasal instillation at 4 to 6 weeks of age to induce lung tumorigenesis. This route of Cre delivery has been demonstrated to successfully recombine floxed DNA sequences, including the K-Ras LSL allele (12) . Mice were aged for 6, 9, and 12 weeks, and lung 
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than 50% of cells. Intriguingly, although the lack of C-Raf had no effect on the percentage of tumors with increased ERK phosphorylation (Supplementary Fig. 4A) , B-Raf fl/fl ; K-Ras LSL mice displayed fewer lung tumors with pERK positivity (Fig. 2C) . Thus, K-Ras G12D may activate the MAPK pathway in advanced lung tumors through B-Raf signaling.
Because the MAPK pathway is a major regulatory pathway of cell proliferation, we examined proliferation of lung neoplasms at 12 weeks post Ad-Cre infection by Ki-67 immunohistochemistry. The percentage of Ki-67-positive neoplastic cells in C-Raf fl/fl ; K-Ras LSL mice was unchanged ( Supplementary Fig. 4B ). In contrast, proliferation of AAH and early grade adenomas was reduced in B-Raf fl/fl ; K-Ras LSL mice (Fig. 4D) , suggesting that reduced MAPK pathway activation in these tumors may result in impaired proliferation. Thus, although B-Raf is dispensable for initiation of alveolar neoplasms, B-Raf deficiency impairs proliferation of K-Ras 
recombination of raf alleles In Vivo
To confirm that decreased MAPK activation and proliferation in conditional B-Raf knockout tumors is due to B-Raf deficiency, tumor tissue was isolated from mice at end point by laser capture microdissection and genotyping PCRs were performed on the DNA isolated from these tissues. Notably, in 50% of tumors (5 of 10) a recombined floxed B-Raf product strongly impairs the development of SOS-driven epidermal tumors (17) .
MaPK activity and Proliferation of Lung Neoplasms
To evaluate Raf/MEK/ERK pathway activation, immunohistochemistry was employed to measure phosphorylated ERK in lung tumors of K-Ras LSL mice harboring conditional Raf knockout alleles. Premalignant lesions of the lung have been previously reported to lack increased levels of pERK, whereas advanced tumors harboring concomitant loss of the tumor suppressor gene p53 demonstrated augmented activation of the MAPK pathway (18) (19) (20) . Similarly, AAH, BH, and adenomas at 12 weeks post Ad-Cre infection showed no elevation of pERK levels compared to surrounding normal lung epithelia in all genotypes (data not shown). Thus, we examined pERK expression in lung tumors of the survival cohorts, as these tumors presumably had progressed to more advanced stages. Although the majority of tumors at the time of death of these animals displayed no increase in pERK staining (•80%; Fig. 4C, Supplementary Fig. 4A ), a fraction of tumors exhibited elevated levels of pERK. We devised a grading system to assess the intensity of ERK phosphorylation in lung tumors. Weak pERK staining in less than 25% of cells in a tumor was considered low-intensity staining. Weak to moderate staining in more than 25% of cells or strong pERK positivity in less than half of the tumor was counted as medium-intensity staining. Tumors with high-intensity pERK staining displayed strong staining for pERK in more T1 T2  T1  T1 T2  T2  T3  T6  T5  T4  T7 T8 T9 T1  T1  T1  T2  T2  T2  T3  T6  T5  T4  T7 T8 T1 T2  T1  T1 T2  T2  T3  T6  T5  T4  T7 T8 T9 T1  T1  T1  T2  T2  T2  T3  T6  T5  T4  T7 T8 T1 T2  T1  T1 T2  T2  T3  T6  T5  T4  T7 T8 T9 T1  T1  T1  T2  T2  T2  T3  T6  T5  T4  T7 T8 T1 T2  T1  T1 T2  T2  T3  T6  T5  T4  T7 T8 T9 T1  T1  T1  T2  T2  T2  T3  T6  T5  T4  T7 T8 T1 T2  T1  T1 T2  T2  T3  T6  T5  T4  T7 T8 T9 T1  T1  T1  T2  T2  T2  T3  T6  T5  T4  T7 T8 T1 T2  T1  T1 T2  T2  T3  T6  T5  T4  T7 T8 T9 T1  T1  T1  T2  T2  T2  T3  T6  T5  T4  T7 T8 
Statistical Analysis
All experiments were repeated at least 3 times and done in triplicate. Statistical analysis was performed with the Mantel-Cox test or Student's t-test; P < 0.05 was accepted as significant. GraphPad Prism software was used for both analyses. Data are shown as mean; error bars represent the standard error; *, P < 0.05; **, P < 0.01; ***, P < 0.001. adenocarcinoma could not be addressed in this study and remains to be determined.
Our findings support the model that K-Ras G12D signals through C-Raf in both bronchiolar hyperplasia and adenomatous alveolar hyperplasia cells or a common progenitor cell type and that the loss of C-Raf impinges on the initiation of both of these preneoplasms. B-Raf, on the other hand, may participate once a cell fate decision has been made. Indeed, germline and conditional B-Raf and C-Raf knockout mice revealed that these Raf proteins serve different functions in distinct cell types (24) . Alternatively, the absence of B-Raf could influence this cell fate decision, leading to fewer bronchiolar hyperplasias. Interestingly, it has been noted that the importance of individual Raf proteins changes depending on the transformation status of a cell (25) . Thus, it is plausible that B-Raf is dispensable for tumor initiation but becomes more important once an epithelial cell has been transformed by K-Ras G12D .
Recently, three studies reported that ATP-competitive Raf inhibitors have unexpected adverse effects in Ras-mutant cancer cells, where they promote Raf dimerization and MAPK hyperactivation (26) (27) (28) . These pharmacological results argue that treatment of patients with Raf inhibitors could be detrimental if the Ras mutation status is unknown. However, our genetic analysis supports Raf proteins, and especially C-Raf, as potential therapeutic targets in K-Rasmutant lung cancer. Because genetic ablation is not equivalent to pharmacological inhibition, future experiments are required to determine whether our genetic data are accurately predictive of a pharmacological response to complete Raf inhibition. In addition, once the genetic tools become available, the effect of Raf ablation in established tumors can be addressed. Patients treated with currently available Raf inhibitors often develop therapy-induced squamous cell carcinoma, potentially due to increased MAPK activation as mentioned above. Thus, our finding of the critical role of C-Raf in K-Ras G12D -mediated lung cancer development should stimulate further research to validate C-Raf as a therapeutic target and prompt the development of Raf inhibitors without detrimental side effects. Given the importance of C-Raf during tumor initiation, such agents may be useful not only for the treatment of advanced cancer but also as chemopreventive agents.
Previously, B-Raf was considered the main activator of the MAPK pathway because deletion of B-Raf, but not A-Raf or C-Raf, abrogated ERK phosphorylation in several cell types (23) . However, our data show that in the context of K-Ras G12D -expressing mutant epithelial cells, C-Raf plays a more prominent role than B-Raf. Interestingly, two other reports implicated C-Raf as the major Raf member downstream of oncogenic Ras in different cancer types. In melanoma cells, oncogenic N-Ras signals to MEK/ERK via C-Raf (25) . Moreover, C-Raf was required for the development and maintenance of squamous cell carcinomas induced by either an activated SOS transgene or 7,12-dimethyl-benz(a)anthracene (DMBA)-12-O-tetradecanoylphorbol-13-acetate (TPA) carcinogenesis protocol (17) . Thus, in several oncogenic contexts C-Raf appears to be the most critical Raf family member, providing an attractive target to inhibit during chemoprevention and intervention studies.
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